"Statistical Considerations for Clinical Trials During COVID-19: Blinded Data Review for Adaptive Estimands (Part III)" by Qing Liu

Selected Works of Karl E. Peace

Follow Contact

Article

Statistical Considerations for Clinical Trials During COVID-19: Blinded Data Review for Adaptive Estimands (Part III)

Qing Liu
Karl E. Peace, Georgia Southern University

Link

Document Type

Article

Publication Date

4-15-2020

Disciplines

Biostatistics,
Environmental Public Health,
Epidemiology and
Public Health

Abstract

As stated early in part I of the article, the focus of this article is for moderately COVID-19 affected ongoing trials where no formal interim analysis is planned. This requires a comprehensive assessment of each attribute of an estimand affected by unplanned trial modifications due to COVID-19. In addition, a formal process for adaptive statistical analysis planning, as described by Liu and Chi (2010a) and restated below, is also required.

Citation Information

Qing Liu and Karl E. Peace. "Statistical Considerations for Clinical Trials During COVID-19: Blinded Data Review for Adaptive Estimands (Part III)" LinkedIn (2020)
Available at: http://works.bepress.com/karl_peace/351/